Lung Cancer Clinical Trials in Dallas

Showing 641-660 of 660 trials

Study of XL281 in Adults With Solid Tumors

NCT00451880

The purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor (including c-Raf, B-Raf, and the activated mutant B-RafV600E) XL281, how often it should be taken, and how well subjects with cancer tolerate XL281. This study will also determine how the body reacts to XL281 when it is taken with and without food, and with and without Pepcid (famotidine), a drug that inhibits stomach acid production.

CancerNon-small-cell Lung CancerColorectal Cancer+2 more

Exelixis180 participantsStarted Feb 2007

Scottsdale, Arizona, United States • Tampa, Florida, United States • Detroit, Michigan, United States +3 more locations

COMPLETEDPhase 2< 1 mile

A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC

NCT00343291

The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with two different regimens of paclitaxel and carboplatin chemotherapy.

Non-Small Cell Lung Cancer

Eli Lilly and Company121 participantsStarted Dec 2006

Decatur, Alabama, United States • Huntsville, Alabama, United States • Scottsdale, Arizona, United States +40 more locations

Study of XL281 in Adults With Solid Tumors

A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC

Lung Cancer Trials in Other Cities

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment

Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer

Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer

Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide

Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Other Conditions in Dallas